Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) released its quarterly earnings results on Monday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Trading Up 29.5 %

NASDAQ:AVXL traded up $2.55 during midday trading on Monday, hitting $11.18. 7,401,592 shares of the company traded hands, compared to its average volume of 1,243,473. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $11.50. The firm has a market capitalization of $948.02 million, a P/E ratio of -22.36 and a beta of 0.73. The firm's fifty day moving average is $7.69 and its 200-day moving average is $6.19.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AVXL. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Anavex Life Sciences in a report on Wednesday, November 27th. D. Boral Capital reissued a "buy" rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.